interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Ubrogepant

Generic competition · all medicines · read 12 November 2026

Is there a generic of Ubrogepant, and who makes it?

Ubrogepant appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Ubrogepant1 dosage-form group in the Orange Book
0generic makers listed
  1. Ubrogepant appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Ubrelvy. No generic is listed as marketed.

201520202025203020352040204501brand 2019data datePatent 9499545 listed to expire 10 November 2031Patent 9833448 listed to expire 10 November 2031Patent 8754096 listed to expire 19 July 2032Patent 8912210 listed to expire 23 December 2033Patent 12220408 listed to expire 30 January 2035Patent 12458632 listed to expire 30 January 2035Patent 11925709 listed to expire 30 January 2035Patent 12168004 listed to expire 30 January 2035Patent 10117836 listed to expire 30 January 2035Patent 12310953 listed to expire 30 January 2035Patent 12458633 listed to expire 30 January 2035Patent 11717515 listed to expire 22 December 2041Patent 12329750 listed to expire 22 December 2041Patent 12194030 listed to expire 22 December 2041Patent 11857542 listed to expire 22 December 2041Patent 12070450 listed to expire 22 December 2041
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 10 November 2031Patent 9499545 drug substance
  • 10 November 2031Patent 9833448
  • 19 July 2032Patent 8754096 drug substance
  • 23 December 2033Patent 8912210 drug substance
  • 30 January 2035Patent 12220408 drug product
  • 30 January 2035Patent 12458632 drug product
  • 30 January 2035Patent 11925709 drug product
  • 30 January 2035Patent 12168004 drug product

8 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.